RBC
IMMU

Ronald Blue & Co’s Immunomedics Inc IMMU Stock Holding History

Ronald Blue & Co’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-11,451
Closed -$29K – 242
2016
Q1 		$29K Buy
+11,451
New +$25.8K ﹤0.01% 200

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ronald Blue & Co's IMMU Position: Q2 2016 in Review

Ronald Blue & Co sold out of Immunomedics Inc (IMMU) in Q2 2016, closing a stake of 11,451 shares — an estimated $29K sold.

Ronald Blue & Co first reported a position in IMMU in Q1 2016 and held it in 1 quarter. The position peaked at $29K in Q1 2016. 110 funds tracked by Wall St. Rank hold IMMU as of Q2 2016.

  • Ronald Blue & Co reported no remaining Immunomedics Inc position as of Q2 2016 after selling out during the quarter.
  • Ronald Blue & Co sold 11,451 Immunomedics Inc shares in Q2 2016, an estimated $29K.
  • Ronald Blue & Co first reported a position in Immunomedics Inc in Q1 2016 and held it in 1 quarter.
  • Ronald Blue & Co's Immunomedics Inc position peaked at $29K in Q1 2016.
  • 110 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2016.

Based on Ronald Blue & Co's 13F filing for Q2 2016, filed 10 Aug 2016.